NMN & NR for Brain Health: What the Studies Actually Show

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two NAD+ precursors that anchor almost every "brain health" and "anti-aging" supplement on the shelf. The pitch is consistent: NAD+ is central to how cells make energy, it falls with age, and "refuelling" it should protect — even sharpen — an aging brain. The biochemistry behind that story is real. The human cognitive evidence is not. This page separates what these molecules demonstrably do (raise a biomarker, with a clean safety record) from what they are sold to do (clear fog, protect memory, restore mental sharpness) — and on the second list, the controlled trials keep coming back null.

The honest framing first: both NMN and NR are supplements, not approved drugs, sold for the general healthy population while most of the brain data come from preclinical animal work or small trials in disease populations. "Brain health" is not a measured endpoint on a supplement label — it is a marketing phrase. We hold these claims to the same bar as any medicine: did a randomized trial measuring cognition show a benefit?

What NMN and NR are — and the one thing they reliably do

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme at the center of cellular metabolism. NMN and NR are precursors the body converts into NAD+. The single most replicated fact about them is that they raise circulating NAD+. A physiologic study of an oral NMN formulation in overweight or obese middle-aged and older adults confirmed it augments blood NAD+ and is well tolerated⁴. NR does the same and has been characterized across multiple studies as a bioavailable, generally safe precursor¹⁰. A broader systematic review of NAD-based interventions across clinical conditions agrees on the safety read: these are generally well-tolerated¹¹.

So the foundation is solid: take the precursor, the NAD+ number goes up. The entire question is whether moving that number does anything you can feel or measure in the brain. That is where the marketing and the evidence diverge.

This biomarker-versus-outcome gap is the whole story of NAD+ and cognition, and we lay out the full version in the pillar guide, Does NAD+ Help Brain Fog? An Evidence Check.

The human cognition trials: biomarker up, thinking unchanged

The most directly relevant new data come from a 2025 crossover, double-blind, randomized placebo-controlled trial of oral NR (1 g/day for 8 weeks) in older adults with subjective cognitive decline and mild cognitive impairment — exactly the people the "protect your brain" pitch targets. The result is the cleanest possible illustration of the gap: NR was safe and lowered plasma pTau217 (an Alzheimer's-related biomarker) by about 7% versus placebo, yet produced no improvement in cognition on the primary neuropsychological battery, on digital cognitive games, or on other plasma markers¹. A biomarker moved. The thinking did not.

That mirrors the earlier, equally relevant trial: a randomized placebo-controlled study of NR in older adults with mild cognitive impairment found that oral NR raised NAD+ but produced no cognitive improvement versus placebo². And in long-COVID — a population defined partly by "brain fog" — a 2025 RCT of NR raised NAD+ roughly 3-fold and still found no significant cognitive or fatigue benefit versus placebo³. Three trials, three foggy or at-risk populations, the same pattern.

It is worth being precise about what these trials are not. None of them is a large, long, definitive study in healthy adults — the population most supplement buyers belong to. The honest summary is not "proven useless"; it is "the best controlled tests so far have not shown the cognitive benefit the products imply, despite reliably hitting the biomarker." For a healthy person with everyday fog, that means the evidence is currently thin-to-absent — not encouraging.

The "physical energy" case is also weak

Because brain and body energy claims travel together, the physical-performance data are a useful cross-check — and they don't rescue the story. A 2025 systematic review and meta-analysis of NMN and NR randomized trials concluded that current evidence does not support either precursor for preserving muscle mass or physical function in adults over 60: no significant effect on grip strength, gait speed, or sit-to-stand performance⁵. Pooled across trials, the "energy and vitality" promise is largely null on the body side too. We unpack the fatigue angle in NAD+ for Cognitive Energy & Fatigue.

The trials people cite back — read the fine print

Two kinds of "positive" studies get quoted to defend NMN/NR for the brain. Both deserve careful reading.

Combination cocktails. Randomized phase-II trials of "combined metabolic activators" reported genuine cognitive improvement — an ADAS-Cog gain in Alzheimer's patients⁶ and multi-omics-supported cognitive improvement in Parkinson's disease⁷. These are real, well-conducted trials. But the intervention is NR combined with L-serine, N-acetylcysteine, and L-carnitine — not NR alone. You cannot credit the NAD+ precursor for the effect, and results in neurodegenerative-disease patients do not transfer to a healthy person managing everyday foggy thinking. A metabolic review of NAD+ precursors for Alzheimer's reaches the same cautious conclusion: mechanistically motivated, not yet proven as a standalone treatment⁸.

Animal studies. Preclinical work is genuinely encouraging — for example, NMN prevented diabetes-induced cognitive impairment and protected hippocampal neurons in mice⁹. This is exactly why the molecules are worth studying. But "protected neurons in a diabetic mouse" is a mechanistic starting point, not evidence that a capsule sharpens a healthy human mind. Treating animal or cell data as if it were a human result is the single most common way NMN/NR brain claims are oversold.

Does the route or precursor choice change the answer?

A predictable rebuttal is that the wrong precursor or wrong delivery is to blame — that NMN beats NR, or that a nasal or IV form would reach the brain where pills can't. The evidence doesn't support either escape hatch. NMN and NR both reliably raise NAD+, and the meta-analytic and trial data show no convincing cognitive edge for one over the other⁵. And there is no rigorous randomized trial of intranasal or intravenous NAD+ for cognition showing a benefit that oral precursors lack — the route changes the marketing, not the proven result. We examine the delivery claim directly in Nasal NAD+ for Focus: Is There Evidence?, and the oral "enhanced absorption" version in Liposomal NAD+ for the Brain: The Absorption Reality. The "wrong dose" version of the same rebuttal fares no better — the dose-ranging trials raised NAD+ without moving cognition, which we cover in NAD+ Dosing for Cognitive Benefits.

What this means if you're shopping for "brain health"

The evidence-first order of operations does not start on a supplement shelf. Persistent fog and dullness are usually symptoms sitting on top of a treatable cause — and finding that cause beats any NAD+ precursor:

• •Protect sleep first. Sleep deprivation produces clear, dose-dependent declines in attention, working memory, and processing speed; it is the single best-supported lever for mental sharpness¹².
• •Rule in a reversible cause. Thyroid dysfunction independently affects mood and cognition¹³; vitamin B12 deficiency is a classic, reversible cause of fatigue and cognitive slowing¹⁴; post-viral illness such as long-COVID produces measurable impairment too³. We walk through this in What Actually Causes Brain Fog?.
• •Set honest expectations for the supplement itself. NMN and NR are safe and reliably raise NAD+⁴¹¹ — but they have not beaten placebo for cognition in the best trials available¹²³. If you still want to weigh them against the alternatives, see NAD+ vs Nootropics for Focus and our best cognitive-energy picks.

The bottom line

NMN and NR are a near-perfect example of strong mechanism outrunning weak human evidence. They are bioavailable, well-tolerated, and reliably raise NAD+ — that part is settled. But in the best controlled human trials of the actual brain claim, they have lowered an Alzheimer's biomarker without improving cognition, failed to beat placebo in mild cognitive impairment, and failed to lift long-COVID fog despite tripling NAD+. The genuinely positive cognitive trials used multi-ingredient cocktails in disease populations, and the most striking brain results remain confined to animals. None of that adds up to "proven for brain health" — it adds up to "promising mechanism, unproven product." If your goal is a clearer head, the highest-yield moves are still the unglamorous ones: protect your sleep and rule in a treatable cause before you reach for a precursor.